Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.74 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.74 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808878 | 1.00 | CYP2C9 (0.74) | CYP2C9KDM4EABCB11TBXA2RADRA1A | |
| SCHEMBL8518663 | 0.92 | ABCB11 (0.61) | CYP2C9KDM4EABCB11TBXA2RADRA1A | |
| SCHEMBL8913291 | 0.87 | CYP2C9 (0.81) | CYP2C9KDM4EABCB11TBXA2RADRA1A | |
| SCHEMBL9485314 | 0.87 | CYP2C9 (0.81) | CYP2C9KDM4EABCB11TBXA2RADRA1A | |
| SCHEMBL7283648 | 0.87 | CYP2C9 (0.81) | CYP2C9KDM4EABCB11TBXA2RADRA1A | |
| SCHEMBL10823894 | 0.86 | CYP2C9 (0.79) | CYP2C9KDM4EABCB11TBXA2RADRA1A | |
| Felodipine SCHEMBL13460298 | 0.86 | CYP2C9 (1.00) | CYP2C9KDM4EABCB11TBXA2RADRA1A | |
| (R)-Felodipine SCHEMBL54486 | 0.86 | CYP2C9 (1.00) | CYP2C9KDM4EABCB11TBXA2RADRA1A | |
| Felodipine SCHEMBL26398 | 0.86 | CYP2C9 (1.00) | CYP2C9KDM4EABCB11TBXA2RADRA1A | |
| Felodipine SCHEMBL920025 | 0.86 | CYP2C9 (1.00) | CYP2C9KDM4EABCB11TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114835632-A | Preparation method and application of clevidipine butyrate intermediate | 广东赛烽医药科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| CN-107449834-B | Method for detecting clevidipine and related substances in fat emulsion injection thereof | 江苏正大丰海制药有限公司 | 2020-04-07 | — | — | CN | claimed |
| CN-114835632-B | Preparation method and application of clevidipine butyrate intermediate | 广东赛烽医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-114835632-B | Preparation method and application of clevidipine butyrate intermediate | 广东赛烽医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-114835632-A | Preparation method and application of clevidipine butyrate intermediate | 广东赛烽医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114835632-A | Preparation method and application of clevidipine butyrate intermediate | 广东赛烽医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-107449834-B | Method for detecting clevidipine and related substances in fat emulsion injection thereof | 江苏正大丰海制药有限公司 | 2020-04-07 | — | — | CN | disclosed |
| EP-3020704-A2 | CRYSTALLINE POLYMORPHS OF CLEVIDIPINE BUTYRATE | Laboratorios Lesvi, S.L. (ES) | 2016-05-18 | — | — | EP | disclosed |
| EP-2386544-B1 | Preparation of dihydropyridines | LESVI LABORATORIOS SL (ES) | 2016-02-10 | — | — | EP | disclosed |
| US-8455655-B2 | Preparation of dihydropyridines | LABORATORIOS LESVI, S.L. (ES) | 2013-06-04 | — | — | US | disclosed |
| WO-2012069989-A1 | PROCESS FOR PREPARATION OF CLEVIDIPINE AND ITS INTERMEDIATE | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| EP-2386544-A1 | Preparation of dihydropyridines | Laboratorios Lesvi, S.L. (ES) | 2011-11-16 | — | — | EP | disclosed |
| US-20110275825-A1 | PREPARATION OF DIHYDROPYRIDINES | LABORATORIOS LESVI, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110253123-A1 | FLOW DIRECTING DEVICE FOR A COOKING APPLIANCE | RATIONAL AG (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-1133473-B1 | NEW MANUFACTURING PROCESS | ASTRAZENECA AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| US-6350877-B1 | MANUFACTURE OF CLEVIDIPINE BY SALT FORMATION ESTERIFICATION | ASTRAZENECA AB (SE) | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275825-A1 | PREPARATION OF DIHYDROPYRIDINES | CACNA1C, CACNA1D, CACNB4 | CYP2C9 187/4885KDM4E 885/4885ABCB11 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.